FDA APPROVES DRUG IN COMBINATION WITH CHEMOTHERAPY FOR OVARIAN CANCER
"
The US Food and Drug Administration has approved a drug in combination with chemotherapy for the treatment of women with ovarian cancer.The approval was based on the phase III GOG-0218 trial, in which women with previously untreated stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube carcinoma who already had surgery received chemotherapy alone (carboplatin and paclitaxel), Avastin (15 mg/kg) plus chemotherapy followed by placebo alone, or Avastin plus chemotherapy followed by Avastin alone for a total of up to 22 cycles.
"